Join Us for the Next NEO Grand Rounds on Postnatal Steroids: Balancing Neurological Risks of Treatment vs. Disease

Pediatrix’s commitment to clinical and research excellence is evidenced by our comprehensive educational and professional development opportunities offered online or during live sessions.

The Pediatrix® Neonatology Grand Rounds series addresses pertinent controversial issues that influence the clinical practice of newborn medicine. Webinars are held on the first Wednesday of every month from 4 to 5 p.m. Eastern Time.

On May 7, Nehal A. Parikh, D.O., M.S., will examine “Postnatal Steroids: Balancing Neurological Risks of Treatment vs. Disease.”

There is currently a large gap in research and clinical evidence as to the clear benefit/risk ratio of administering moderate dose postnatal corticosteroid therapy in very preterm infants at high risk of bronchopulmonary dysplasia (BPD) between seven and 21 days of age and actual clinical practice. Some clinicians incorrectly believe that any but the lowest dose (e.g., the Dexamethasone: A Randomized Trial study) of postnatal steroids are harmful for the developing brain and neurodevelopment. However, BPD is worse and, therefore, reducing BPD with steroids will reduce the risk of long-term neurodevelopmental impairments when treating the highest risk infants.

In this session, we will:

• Describe how individual risk of BPD influences the effect of postnatal corticosteroids (PNC) on neurodevelopmental impairment/death.
• Distinguish the neurostructural and neurodevelopmental effects of PNC treatment from underlying BPD to make individualized decisions about PNC timing, dose and duration that optimizes the balance of benefits versus harms.

Click here to register for this session.

Dr. Parikh is a neonatologist, neuroscientist and professor of pediatrics at Cincinnati Children’s and the University of Cincinnati College of Medicine. He is the founding director of the Neurodevelopmental Disorders Prevention Center at Cincinnati Children’s, whose vision is to prevent neurodevelopmental disorders in high-risk newborns through early, accurate prediction and targeted treatment soon after birth. Dr. Parikh has a keen interest in BPD, as it is a leading determinant of neurodevelopmental impairments in preterm infants. He has conducted two randomized trials of postnatal corticosteroids in infants with evolving BPD and numerous studies examining the effects of both BPD and steroids on brain structure and neurodevelopmental outcomes. He is currently leading the largest cohort of very preterm infants with advanced brain MRI at term-equivalent age and neurodevelopmental and cardiopulmonary outcomes to age 8 to enable accurate early prediction of neurodevelopmental disorders and understand the long-term impact of BPD and postnatal steroids.

Please plan to join us for this important webinar and check out our catalog of previous webinars available on demand.

Accreditation

The Pediatrix Center for Research, Education, Quality and Safety is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Pediatrix Center for Research, Education, Quality and Safety designates this Internet Live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Pediatrix Center for Research, Education, Quality and Safety is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

The Pediatrix Center for Research, Education, Quality and Safety designates this Internet Live activity for a maximum of 1 nursing contact hour. Participants should claim only the credit commensurate with the extent of their participation in the activity.